Magnesium Migraine Randomized Trial: What the Evidence Says

Quick Answer

Magnesium Migraine Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Increased estradiol levels during pregnancy and breastfeeding are hypothesized to enhance susceptibility to Cortical Spreading Depression (CSD), thereby triggering or worsening aura attacks. [Braca Simone (2026); evidence level 1]
• Evidence regarding therapies such as CGRP-targeted monoclonal antibodies (mAbs), gepants (CGRP receptor antagonists), and triptans (serotonin 5-HT1B/1D receptor agonists) is mixed, with reported sex differences in efficacy, recurrence, and adverse events. [Braca Simone (2026); evidence level 1]
• Migraine is a chronic, disabling neurovascular disorder characterized by recurrent episodes of moderate-to-severe headache, typically unilateral and pulsating in quality, and frequently associated with nausea, vomiting, photophobia, and phonophobia. [Santangelo Domenico (2026); evidence level 3]
• These processes result in peripheral and central sensitization of nociceptive pathways, thereby amplifying pain perception and contributing to migraine chronicization. [Santangelo Domenico (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For magnesium migraine randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Braca Simone (2026). Sex-specific management of migraine a systematic review and consensus statement from the European Headache Federation (EHF). DOI: 10.1186/s10194-026-02350-x. PMCID: PMC13126917. PMID: 41998499. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC13126917/
• Santangelo Domenico (2026). Dietary Modulation of Migraine: Metabolic, Neuroinflammatory and Microbiota-Mediated Mechanisms. DOI: 10.3390/jcm15041476. PMCID: PMC12942355. PMID: 41753160. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12942355/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.